Dr. Dummer on COMBI-AD Trial Results in BRAF-Mutant Melanoma

Reinhard Dummer, MD
Published Online: Tuesday, Sep 12, 2017



Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

This is a prospective randomized placebo-controlled trial of 900 enrolled patients who had previously undergone complete resection of all metastatic disease. They were then randomized to receive the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) or placebo. The treatment duration was 1 year and the primary endpoint was relapse-free survival (RFS).

There was a clear advantage for the combination over placebo, Dummer explains. The hazard ratio was below 0.5. Other endpoints, aside from RFS, were positive, including distant metastases-free survival and overall survival.  

<<< View more from the 2017 ESMO Congress


Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

This is a prospective randomized placebo-controlled trial of 900 enrolled patients who had previously undergone complete resection of all metastatic disease. They were then randomized to receive the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) or placebo. The treatment duration was 1 year and the primary endpoint was relapse-free survival (RFS).

There was a clear advantage for the combination over placebo, Dummer explains. The hazard ratio was below 0.5. Other endpoints, aside from RFS, were positive, including distant metastases-free survival and overall survival.  

<<< View more from the 2017 ESMO Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x